

## Aditxt Therapeutics (NASDAQ: ADTX)

October 24, 2022

### Aditxt (ADTX) Neutral Rated : Announces the initiation of GMP manufacturing for ADI-100

*Jason H. Kolbert*  
Managing Director and Senior Analyst  
jkolbert@dawsonjames.com

Aditxt announced that its program Adimune has initiated the GMP manufacturing of drug candidate ADI-100 as a key milestone toward its goal to begin first-in-human trials (psoriasis) during the second half of 2023. We also note the completion of the 50:1 reverse stock split and \$20M capital raise.

#### Investment Highlights

**ADI-100:** Adimune’s approach is to prevent the immune system attacks by restoring immune tolerance and addressing the root cause of skin cell build-ups. Treatment with ADI-100 reduced skin thickening by 69% and scaling by 38% over a 10-day study period in an established psoriasis model.

**Reverse Stock Split (1 for 50) and \$20M Capital raise Completed.** On September 20 Aditxt closed the previously announced public offering of 3.2M shares of its common stock and warrants (to purchase up to 3.3M shares of its common stock at a combined offering price to the public of \$6.00 per share), and associated warrant. The warrants have an exercise price of \$6.00 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance.

**Aditxt Proposes an Acquisition:** Aditxt entered into a transaction agreement to acquire (a subsidiary of), AiPharma Global. AiPharma develops antiviral therapies across a broad spectrum of infectious diseases. This includes rights to Avigan/Reequon/Qifenda and all formulations of favipiravir, a broad-spectrum oral antiviral drug that targets COVID-19 and other infectious diseases. We have not yet included any revenues or expenses for this program.


**Valuation:** Our valuation for Aditxt is driven by diagnostic testing and the expansion of that testing into the type 1 diabetes at-risk testing market as well as some Covid testing. One could argue that a battery of new immune status tests that may be developed by the company represents the future of diagnostics. Our operating model applies a 30% to 50% risk cut, which is in addition to the 30% risk rate we use in our valuation models: free cash flow to the Firm (FCFF), discounted EPS (dEPS), and Sum-of-the-Parts (SOP). We select 30% for micro-capitalized growth companies and this represents our highest risk rate. The result of these three models is then equal-weighted and averaged and rounded to the nearest whole number to provide a 12-month target price.

**Risks to our thesis** include: (1) commercial; (2) financial; (3) intellectual property; (4) regulatory and (5) OEM and/or manufacturing. We review these risks in the Risks Analysis section of this report.



Source: Barron's: We Need to Be Smarter About Covid-19 Immunity by Amro Albanna

Stock Data			
52-Week Range	\$2.58	-	\$136.00
Shares Outstanding (mil.)	2.4		
Market Capitalization (mil.)	\$7		
Enterprise Value (mil.)	-\$3		
Debt to Capital	0%		
Book Value/Share	-\$0.58		
Price/Book	-		
Average Three Months Trading Volume (K)	54		
Insider Ownership	2.0%		
Institutional Ownership	12.5%		
Short interest (mil.)	9.9%		
Dividend / Yield	\$0.00/0.00%		



## Risk Analysis

**Regulatory Risk.** There can be no assurances that the company will be able to secure the required regulatory approvals to support its business.

**Commercial risk.** The focus of the company is on successfully developing its products and bringing them to the market. Competition may be intense from external players as well as customers who choose to “build it themselves.”

**Financial risk.** The company may need to raise capital in the marketplace relatively soon. There can be no assurance that the company will be able to raise capital and do so on favorable terms successfully.

**Intellectual property risk.** The company may have to defend its patents and technical know-how, and there can be no assurances that the patents will not be infringed or will be held as valid if challenged, and the company may infringe on third parties' patents.

**OEM and/or manufacturing risk.** Original Equipment Manufacturers (OEMs) may decide to make products themselves, and, as such, terminate production contracts before completion, creating revenue shortfalls. Manufacturing risks include the ability to produce and do so in a competitive, timely, and efficient way.


**Exhibit 1. Income Statement**

ADTX., Inc. Income Statement (\$000)																
YE Dec. 31	2020A	2021A	1Q22A	2Q22A	3Q22E	4Q22E	2022E	2023E	2024E	2025E	2026E	2027E	2028E	2029E	2030E	
<b>Revenue (\$000)</b>																
COVID-MaB Testing		-	210	215	346	642	1,414	1,428	2,885	2,913	4,414	4,458	6,003	6,063	6,124	
<b>Point of Care Diagnostics</b>									15,000	15,000	15,000	15,000	15,000	15,000	15,000	
<b>Early Anti-Viral Treatment</b>									5,000	20,000	20,000	20,000	20,000	20,000	20,000	
Type 1 Diabetes MaB Testing			-	-	-	-	-	-	-	9,932	20,063	30,395	40,932	51,677	62,632	
Immune Tolerance Platform Technology																
<b>Total Revenues</b>	-	105	210	215	346	642	1,414	1,428	22,885	47,845	59,477	69,853	81,935	92,740	103,756	
<b>Expenses</b>																
COGS	-	78	188	175	35	64	462	466	7,475	15,628	19,427	22,816	26,763	30,292	33,890	
<b>% COGS</b>			10%	10%	10%	10%	33%	33%	33%	33%	33%	33%	33%	33%	33%	
Gross Profit	-	27	22	40	312	578	952	962	15,410	32,217	40,049	47,037	55,172	62,448	69,866	
Sales (Advertising & Marketing) expense	12	335	87	834	750	1,329	3,000	5,000	6,000	6,120	6,242	6,367	6,495	6,624	6,757	
General and administrative	7,852	22,084	4,624	3,789	1,500	(3,913)	6,000	8,000	9,000	9,180	9,364	9,551	9,742	9,937	10,135	
Research & Development	82	5,043	1,428	1,188	625	(741)	2,500	4,000	4,080	4,162	4,245	4,330	4,416	4,505	4,595	
Impairment on Notes receivable		14,500														
<b>Total expenses</b>	<b>8,872</b>	<b>41,962</b>	<b>6,139</b>	<b>5,811</b>	<b>2,875</b>	<b>(3,325)</b>	<b>11,500</b>	<b>17,000</b>	<b>19,080</b>	<b>19,462</b>	<b>19,851</b>	<b>20,248</b>	<b>20,653</b>	<b>21,066</b>	<b>21,487</b>	
<b>Operating Profit</b>	<b>(8,872)</b>	<b>(41,935)</b>	<b>(6,117)</b>	<b>(5,771)</b>	<b>(2,563)</b>	<b>3,903</b>	<b>(10,548)</b>	<b>(16,038)</b>	<b>(3,670)</b>	<b>12,756</b>	<b>20,199</b>	<b>26,789</b>	<b>34,520</b>	<b>41,382</b>	<b>48,379</b>	
<b>Oper Margin</b>																
Interest expense	(10)	(93)	(15)	(82)			(97)	-	-	-	-	-	-	-	-	
Amortization of Debt Discount	1	3	14	6			20	-	-	-	-	-	-	-	-	
Other (loss)	(268)	(4,346)	59	(3)			56	-	-	-	-	-	-	-	-	
<b>Pre-tax income</b>	<b>(9,149)</b>	<b>(46,371)</b>	<b>(6,059)</b>	<b>(5,850)</b>	<b>(2,563)</b>	<b>3,903</b>	<b>(10,569)</b>	<b>(16,038)</b>	<b>(3,670)</b>	<b>12,756</b>	<b>20,199</b>	<b>26,789</b>	<b>34,520</b>	<b>41,382</b>	<b>48,379</b>	
<b>Pretax Margin</b>																
Income Tax (Benefit)								(3,208)	(918)	3,572	6,060	8,305	11,046	14,484	17,900	
<b>Tax Rate</b>			0%	0%	0%	0%	0%	20%	25%	28%	30%	31%	32%	35%	37%	
<b>GAAP Net Income</b>	<b>(9,149)</b>	<b>(46,371)</b>	<b>(6,059)</b>	<b>(5,850)</b>	<b>(2,563)</b>	<b>3,903</b>	<b>(10,569)</b>	<b>(12,831)</b>	<b>(2,753)</b>	<b>9,184</b>	<b>14,139</b>	<b>18,484</b>	<b>23,473</b>	<b>26,898</b>	<b>30,478</b>	
<b>GAAP-EPS</b>	<b>(1.33)</b>	<b>(2.43)</b>	<b>(0.14)</b>	<b>(0.13)</b>	<b>(0.05)</b>	<b>0.08</b>	<b>(0.24)</b>	<b>(0.25)</b>	<b>(0.05)</b>	<b>0.18</b>	<b>0.28</b>	<b>0.36</b>	<b>0.46</b>	<b>0.52</b>	<b>0.59</b>	
Non GAAP EPS (dil)	(1.33)	(1.56)	(0.14)	(0.13)	(0.05)	0.08	(0.24)	(0.25)	(0.05)	0.18	0.28	0.36	0.46	0.52	0.59	
Wgtd Avg Shrs (Bas) - '000s	6,903	19,091	44,581	45,560	45,651	45,742	45,384	45,972	46,340	46,712	47,087	47,465	47,846	48,230	48,617	
Wgtd Avg Shrs (Dil) - '000s	6,903	32,123	50,601	50,702	50,804	50,905	50,753	50,855	50,956	51,058	51,160	51,263	51,365	51,468	51,571	

Source: Dawson James estimates, company reports

**Important Disclosures:**

**Price Chart:**



**Price target and ratings changes over the past three years:**

- Initiated – Buy – February 4, 2021 – Price Target \$14.00
- Update – Buy – March 25, 2021 – Price Target \$14.00
- Update – Buy – April 8, 2021 – Price Target \$14.00
- Update – Buy – June 1, 2021 – Price Target \$14.00
- Update – Buy – July 12, 2021 – Price Target \$14.00
- Price Target Change – Buy – August 16, 2021 – Price Target Lowered to \$8.00 from \$14.00
- Price Target Change – Buy – November 18, 2021 – Price Target Lowered to \$4.00 from \$8.00
- Price Target Change – Buy – December 23, 2021 - Price Target Raised from \$4.00 to \$6.00
- Update – Buy – April 5, 2022 – Price Target \$6.00
- Price Target Change – Buy – August 16, 2022 – Price Target \$1.00 Price Target Lowered \$6.00 to \$1.00
- Rating Change – Lowering from Buy to Neutral – September 16, 2022 Price Target - NA
- Update – Neutral – October 24, 2022 – Price Target - NA

Dawson James Securities, Inc. (the "Firm") is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

The Firm does not make a market in the securities of the subject company(s). The Firm has engaged in investment banking relationships with the subject company in the prior twelve months, as a manager or co-manager of a public offering and has received compensation resulting from those relationships. The Firm may seek compensation for investment banking services in the future from the subject company(s). The Firm has not received any other compensation from the subject company(s) in the last 12 months for services unrelated to managing or co-managing of a public offering.

Neither the research analyst(s) whose name appears on this report nor any member of his (their) household is an officer, director, or advisory board member of these companies. The Firm and/or its directors and employees may own securities of the company(s) in this report and may increase or decrease holdings in the future. As of October 19, 2022, the Firm as a whole did not beneficially own 1% or more of any class of common equity securities of the subject company(s) of this report. The Firm, its officers, directors, analysts, or employees may affect transactions in and have long or short positions in the securities (or options or warrants related to those securities) of the company(s) subject to this report. The Firm may affect transactions as principal or agent in those securities.

Analysts receive no direct compensation in connection with the Firm's investment banking business. All Firm employees, including the analyst(s) responsible for preparing this report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of the Firm and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.

Although the statements in this report have been obtained from and are based upon recognized statistical services, issuer reports or communications, or other sources that the Firm believes to be reliable, we cannot guarantee their accuracy. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Information about valuation methods and risks can be found in the "Valuation" and "Risk Analysis" sections of this report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. This report is offered for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. Additional information is available upon request.

**Ratings Definitions:**

- 1) **Buy:** The analyst believes the price of the stock will appreciate and produce a total return of at least 20% over the next 12-18 months.
- 2) **Neutral:** The analyst believes the price of the stock is fairly valued for the next 12-18 months.
- 3) **Sell:** The analyst believes the price of the stock will decline by at least 20% over the next 12-18 months and should be sold.

The following chart reflects the range of current research report ratings for all companies, followed by the analysts of the Firm. The chart also reflects the research report ratings relating to those companies for which the Firm has performed investment banking services.

Current as of 19-Oct-22

	Company Coverage		Investment Banking	
Ratings Distribution	# of Companies	% of Total	# of Companies	% of Totals
Market Outperform (Buy)	25	83%	3	12%
Market Perform (Neutral)	4	13%	1	25%
Market Underperform (Sell)	1	3%	0	0%
Total	30	100%	4	13%

**Analyst Certification:**

The analyst(s) whose name appears on this research report certifies that 1) all of the views expressed in this report accurately reflect his (their) personal views about any and all of the subject securities or issuers discussed; and 2) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst in this research report; and 3) all Dawson James employees, including the analyst(s) responsible for preparing this research report, may be eligible to receive non-product or service-specific monetary bonus compensation that is based upon various factors, including total revenues of Dawson James and its affiliates as well as a portion of the proceeds from a broad pool of investment vehicles consisting of components of the compensation generated by investment banking activities, including but not limited to shares of stock and/or warrants, which may or may not include the securities referenced in this report.